2026 Q1 -tulosraportti
55 päivää sitten
‧1 t 1 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·16 t sitten · MuokattuHi, a lot of good weather these days. Now we have reached mid-2026. That was when the medicare application was supposed to be submitted, right? Then it can't be many days into July before we see news about it, can it? If not, then they are not keeping the promise they made to us. How far can they stretch the rope and still call this mid-2026? ASSURE has already been talked about a bit not many weeks ago. Something that is necessary for the application that is to happen to medicare
15.6.But such a weak price movement in IMMNOV on day 2 of a news item. The pattern repeats itself for a stock that hasn't gained proper momentum previously (perhaps exceptions around the previous variant test and hyping? But then I wasn't even aware of the company. I was busy with completely different stocks at that time).- ·12.6.It's been an incredibly long time this stock has been "cheap" in light of expectations for business development. A bit difficult to understand, but the market is the market. One has probably been genuinely frightened before. I don't have any better explanation for this. One should probably expect that sometime in summer/autumn, big things will happen. But of course, the stock carries a certain risk here with a development company. The product development looks finished. Now several approvals and business development going forward remain.
- ·9.6. · MuokattuNews retrieved from AI: "Pancreatic Cancer Action Network (PanCAN) & Aignostics Partnership (June 9, 2026): Today, PanCAN announced a major partnership with AI-pathology company Aignostics. They will be applying advanced AI spatial profiling models to PanCAN's SPARK platform—one of the largest pancreatic cancer datasets in the world. While this does not involve Immunovia directly, industry analysts note that these types of deep-learning AI partnerships are rapidly accelerating the entire biomarker and liquid biopsy market, creating a strong tailwind for targeted early-detection blood tests like PancreaSure."
- ·9.6.Why are only Avanza's pension insurance customers flagged regarding this 10 percent ownership and not also Nordnet's customers? Is it because Nordnet pension insurance customers have a different ownership percentage? That Immunovia highlighted this Avanza ownership in an announcement in May, that doesn't really provide any particular reassurance that anyone larger is involved at all if this is a forest of collected small customers.
10% is the disclosure threshold and as you say, it's a multitude of retail investors, i.e., no major party involved (via Avanza at least). You can see larger individual owners here https://immunovia.com/home/investors/ownership-structure/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
55 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·16 t sitten · MuokattuHi, a lot of good weather these days. Now we have reached mid-2026. That was when the medicare application was supposed to be submitted, right? Then it can't be many days into July before we see news about it, can it? If not, then they are not keeping the promise they made to us. How far can they stretch the rope and still call this mid-2026? ASSURE has already been talked about a bit not many weeks ago. Something that is necessary for the application that is to happen to medicare
- 15.6.But such a weak price movement in IMMNOV on day 2 of a news item. The pattern repeats itself for a stock that hasn't gained proper momentum previously (perhaps exceptions around the previous variant test and hyping? But then I wasn't even aware of the company. I was busy with completely different stocks at that time).
- ·12.6.It's been an incredibly long time this stock has been "cheap" in light of expectations for business development. A bit difficult to understand, but the market is the market. One has probably been genuinely frightened before. I don't have any better explanation for this. One should probably expect that sometime in summer/autumn, big things will happen. But of course, the stock carries a certain risk here with a development company. The product development looks finished. Now several approvals and business development going forward remain.
- ·9.6. · MuokattuNews retrieved from AI: "Pancreatic Cancer Action Network (PanCAN) & Aignostics Partnership (June 9, 2026): Today, PanCAN announced a major partnership with AI-pathology company Aignostics. They will be applying advanced AI spatial profiling models to PanCAN's SPARK platform—one of the largest pancreatic cancer datasets in the world. While this does not involve Immunovia directly, industry analysts note that these types of deep-learning AI partnerships are rapidly accelerating the entire biomarker and liquid biopsy market, creating a strong tailwind for targeted early-detection blood tests like PancreaSure."
- ·9.6.Why are only Avanza's pension insurance customers flagged regarding this 10 percent ownership and not also Nordnet's customers? Is it because Nordnet pension insurance customers have a different ownership percentage? That Immunovia highlighted this Avanza ownership in an announcement in May, that doesn't really provide any particular reassurance that anyone larger is involved at all if this is a forest of collected small customers.10% is the disclosure threshold and as you say, it's a multitude of retail investors, i.e., no major party involved (via Avanza at least). You can see larger individual owners here https://immunovia.com/home/investors/ownership-structure/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
2026 Q1 -tulosraportti
55 päivää sitten
‧1 t 1 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 6.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 7.5. | ||
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·16 t sitten · MuokattuHi, a lot of good weather these days. Now we have reached mid-2026. That was when the medicare application was supposed to be submitted, right? Then it can't be many days into July before we see news about it, can it? If not, then they are not keeping the promise they made to us. How far can they stretch the rope and still call this mid-2026? ASSURE has already been talked about a bit not many weeks ago. Something that is necessary for the application that is to happen to medicare
- 15.6.But such a weak price movement in IMMNOV on day 2 of a news item. The pattern repeats itself for a stock that hasn't gained proper momentum previously (perhaps exceptions around the previous variant test and hyping? But then I wasn't even aware of the company. I was busy with completely different stocks at that time).
- ·12.6.It's been an incredibly long time this stock has been "cheap" in light of expectations for business development. A bit difficult to understand, but the market is the market. One has probably been genuinely frightened before. I don't have any better explanation for this. One should probably expect that sometime in summer/autumn, big things will happen. But of course, the stock carries a certain risk here with a development company. The product development looks finished. Now several approvals and business development going forward remain.
- ·9.6. · MuokattuNews retrieved from AI: "Pancreatic Cancer Action Network (PanCAN) & Aignostics Partnership (June 9, 2026): Today, PanCAN announced a major partnership with AI-pathology company Aignostics. They will be applying advanced AI spatial profiling models to PanCAN's SPARK platform—one of the largest pancreatic cancer datasets in the world. While this does not involve Immunovia directly, industry analysts note that these types of deep-learning AI partnerships are rapidly accelerating the entire biomarker and liquid biopsy market, creating a strong tailwind for targeted early-detection blood tests like PancreaSure."
- ·9.6.Why are only Avanza's pension insurance customers flagged regarding this 10 percent ownership and not also Nordnet's customers? Is it because Nordnet pension insurance customers have a different ownership percentage? That Immunovia highlighted this Avanza ownership in an announcement in May, that doesn't really provide any particular reassurance that anyone larger is involved at all if this is a forest of collected small customers.10% is the disclosure threshold and as you say, it's a multitude of retail investors, i.e., no major party involved (via Avanza at least). You can see larger individual owners here https://immunovia.com/home/investors/ownership-structure/
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt